Inhibikase Therapeutics, Inc. (IKT) Investor Relations Documents

Inhibikase Therapeutics, Inc. (IKT) investor relations documents from the company's IR site: 1 presentation, 39 press releases; latest deck 2026-05-20. Read in-app with summaries. First-party data.

May 2026: Inhibikase Therapeutics is developing IKT-001, a once-daily oral antiproliferative agent for pulmonary arterial hypertension, with Phase 3 trials initiated in Q1 2026.

Investor relations documents — source: company IR site
PublishedTypeDocument
2026-08-11Press releaseInhibikase Therapeutics Announces Second Quarter 2026 Financial Results and Highlights Recent Activity
2026-08-11Press releaseInhibikase Therapeutics Announces Second Quarter 2026 Financial Results and Highlights Recent Activity
2026-07-23Press releaseInhibikase Therapeutics Announces FDA Orphan Drug Designation Granted to IKT-001 for the Treatment of PAH
2026-07-23Press releaseInhibikase Therapeutics Announces FDA Orphan Drug Designation Granted to IKT-001 for the Treatment of PAH
2026-07-14Press releaseInhibikase Therapeutics Announces Sale of $50 Million of Shares Through its At-the-Market (ATM) Facility
2026-07-14Press releaseInhibikase Therapeutics Announces Sale of $50 Million of Shares Through its At-the-Market (ATM) Facility
2026-07-02Press releaseInhibikase Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-07-02Press releaseInhibikase Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-05-20PresentationMay 2026
2026-05-12Press releaseInhibikase Therapeutics Announces First Quarter 2026 Financial Results and Highlights Recent Activity
2026-05-12Press releaseInhibikase Therapeutics Announces First Quarter 2026 Financial Results and Highlights Recent Activity
2026-05-12Press releasePDF
2026-04-07Press releaseInhibikase Therapeutics Announces Enrollment of First Patient in IMPROVE-PAH Global Phase 3 Study of IKT-001 in the Trea
2026-04-07Press releaseInhibikase Therapeutics Announces Enrollment of First Patient in IMPROVE-PAH Global Phase 3 Study of IKT-001 in the Trea
2026-04-03Press releaseInhibikase Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-04-03Press releaseInhibikase Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-03-26Press releaseEarnings Release
2026-03-26Press releaseInhibikase Therapeutics Announces Full Year 2025 Financial Results and Highlights Recent Activity
2026-03-26Press releaseHTML
2026-03-26Press releasePDF
2025-11-20Press releaseInhibikase Therapeutics Announces Pricing of $100 Million Public Offering of Common Stock and Pre-Funded Warrants
2025-11-20Press releaseInhibikase Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
2025-11-20Press releaseInhibikase Therapeutics Advancing IKT-001 to Global Phase 3 Study in Pulmonary Arterial Hypertension
2025-11-20Press releaseInhibikase Therapeutics Announces Pricing of $100 Million Public Offering of Common Stock and Pre-Funded Warrants
2025-11-20Press releaseInhibikase Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
2025-11-20Press releaseInhibikase Therapeutics Advancing IKT-001 to Global Phase 3 Study in Pulmonary Arterial Hypertension
2025-11-14Press releasePDF
2025-08-14Press releasePDF
2025-05-14Press releasePDF
2025-03-27Press releasePDF
2024-11-14Press releaseInhibikase Therapeutics Reports Third Quarter Financial Results and Highlights Recent Activity
2024-11-14Press releaseInhibikase Therapeutics Reports Third Quarter Financial Results and Highlights Recent Activity
2024-11-14Press releasePDF
2024-08-14Press releaseInhibikase Therapeutics Reports Second Quarter Financial Results and Highlights Recent Period Activity
2024-08-14Press releaseInhibikase Therapeutics Reports Second Quarter Financial Results and Highlights Recent Period Activity
2024-08-14Press releasePDF
2024-08-07Press releaseInhibikase Therapeutics to Report Second Quarter 2024 Financial Results on August 14, 2024
2024-08-07Press releaseInhibikase Therapeutics to Report Second Quarter 2024 Financial Results on August 14, 2024
2024-05-15Press releaseInhibikase Therapeutics Reports First Quarter Financial Results and Highlights Recent Period Activity
2024-05-15Press releaseEarnings Release

IKT overview · IKT earnings · IKT financials · IKT KPIs · IKT ownership · IKT peers · IKT filings

Documents published by the company on its investor-relations site; summaries are model-written. Not personalized investment advice.